Results 161 to 170 of about 19,166 (184)

Switching from rituximab to C5 complement inhibitors is safe in AQP4+ NMOSD

Medicom Conference Report MSMilan 2023, 2023
openaire   +1 more source

Phase 1 clinical trial of novel complement C5 inhibitor coversin

Molecular Immunology, 2013
W. Weston-Davies, J.-P. Westwood, M. Nunn   +2 more
openaire   +1 more source

Small Molecule Inhibitors of Complement (C5) Enhance Vaccinia Viral Oncolysis

Journal of Surgical Research, 2013
D. Magge, Z. Guo, M. O'Malley, L. Francis, R. Ravindranathan, D.L. Bartlett   +5 more
openaire   +1 more source

New insight into the effects of heparinoids on complement inhibition by C1-inhibitor

Clinical and Experimental Immunology, 2016
Felix Poppelaars, Jeffrey Damman, Johannes G M Burgerhof   +2 more
exaly  

Kinetics of reaction of human C-inhibitor with the human complement system proteases Cr and Cs

Biochimica Et Biophysica Acta - Biomembranes, 1980
Robert B Sim, G J Arlaud, M G Colomb
exaly  

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Blood, 2008
Robert A Brodsky, Elisabetta Antonioli, Antonio M Risitano   +2 more
exaly  

New Treatment Options for Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab

Seminars in Thrombosis and Hemostasis, 2010
Lothar-Bernd Zimmerhackl, Thérèse Jungraithmayr   +1 more
exaly  

Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement

Molecular Immunology, 2007
Erik Waage Nielsen, Hilde Fure, Georgia Sfyroera   +2 more
exaly  

Hydrodynamic data show that C1̄ inhibitor of complement forms compact complexes with C1̄r and C1̄s

FEBS Letters, 1990
Stephen J Perkins
exaly  

An inhibitor of complement C5 provides structural insights into activation

Proceedings of the National Academy of Sciences of the United States of America, 2020
Martin P Reichhardt, Steven Johnson, Terence Tang   +2 more
exaly